One shot before surgery: could early immunotherapy stop melanoma in its tracks?
NCT ID NCT07448831
First seen Mar 23, 2026 · Last updated May 09, 2026 · Updated 7 times
Summary
This study is testing whether giving a single dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. It includes 49 adults with melanoma that hasn't spread on scans. After surgery, some patients continue standard immunotherapy for a year, and all are monitored for five years to check for cancer return and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA (SKIN CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZ Brussel
RECRUITINGJette, Brussels Capital, 1090, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.